Andrea Lobo,  —

The U.S. Food and Drug Administration (FDA) has cleared Cereno Scientific’s request to launch a global Phase 2b trial of CS1, an oral therapy for people with pulmonary arterial hypertension (PAH). The company expects to begin enrolling patients in the second quarter of 2026, with top-line data anticipated…

People with chronic thromboembolic pulmonary hypertension (CTEPH) who have a high pulmonary arterial wedge pressure (PAWP) — a measure of pressure in the heart’s left atrium, which receives blood from the lungs…

Two proteins associated with the aggregation and activation of platelets may serve as biomarkers of chronic thromboembolic pulmonary hypertension (CTEPH) severity and progression, according to a study conducted in China. The proteins, PAD4 and NOX2, were elevated in platelets of people with CTEPH compared with healthy individuals, suggesting they may…

Treprostinil may help manage pulmonary hypertension (PH) in children who’ve undergone Fontan surgery for congenital heart defects, according to a study in China. The treatment was associated with lower mean pulmonary arterial pressure (PAP) and improved oxygenation — oxygen delivery to tissues. The therapy was well tolerated, with no…

For pregnant women with pulmonary hypertension (PH), higher pulmonary arterial pressure — blood pressure levels in the blood vessels that supply the lungs — is associated with longer hospital stays and a greater chance of being admitted to the intensive care unit (ICU). That’s according to a new study…

Pulmonary endarterectomy (PEA), a surgery to remove blood clots in individuals with chronic thromboembolic pulmonary hypertension (CTEPH), may be more effective in improving pulmonary circulation and heart function than balloon pulmonary angioplasty (BPA), according to a recent study. After treatment, a higher proportion of patients in the BPA group…

Treatment with a combination of sildenafil and statins improved exercise capacity and reduced pulmonary arterial pressure in people with pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) — a condition known for short as COPD-PH — according to a review study by scientists in China. These findings,…

Yutrepia (inhaled treprostinil), an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD), has been prescribed to more than 900 people with PAH and PH-ILD since its approval in the U.S. in May, according to…

Researchers identified two genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers for idiopathic pulmonary arterial hypertension (PAH). The genes are related to ferroptosis, an iron-dependent type of cell death involved in lung diseases and previously associated with PAH. “Our comprehensive analysis…

Boosting the levels of irisin, a protein found at lower levels in people with pulmonary arterial hypertension (PAH), may help slow disease progression by stopping abnormal cell growth and blood vessel remodeling in the lungs, a study has found. “[I]risin is a novel protective factor against PAH development and is…

Corvista Health’s machine-learned algorithm can accurately diagnose pulmonary hypertension (PH) in a noninvasive way by assessing the elevation of mean pulmonary arterial pressure (mPAP), a study showed. The point-of-care system is based on a procedure that can be conducted during medical appointments in under five minutes, with patients…

Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). The effects were tied to a modulation of the NF-kB pathway involved in vascular…